RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) announced today the publication of the first human data from a case study of patients evaluated with its ophthalmic product candidate RGN-259. The data have been published in the May 2010 issue of Archives of Ophthalmology, an American Medical...